B-cell Depletion Using an Anti-CD20 Antibody Augments Antitumor Immune Responses and Immunotherapy in Nonhematopoetic Murine Tumor Models
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The role played by B cells in cancer biology is complex and somewhat controversial. Previous studies using genetically engineered mice suggest that B cells may be immunosuppressive and inhibit tumor rejection. However, the effects of B-cell depletion employing an antibody in mice bearing solid tumors has not been tested owing to difficulties in making an effective antimouse CD20 antibody (similar to rituximab). Injection of a newly developed antimouse CD20 antibody was effective in depleting circulating B cells from blood and lymph nodes, although depletion was less complete in the spleen. B-cell depletion slowed the growth of new solid tumors (not expressing CD20) and retarded the growth of established tumors but did not induce tumor regression. However, when the antibody was combined with an active immunotherapy approach using an adenovirus vaccine expressing the human papilloma virus-E7 gene (Ad.E7) in mice bearing TC1 tumors (murine lung cancer cells expressing human papilloma virus-E7), we noted enhanced antitumor effects and increased numbers of tetramer+/CD8+ T cells within the spleens and activated CD8+ T cells within tumors. B-cell depletion using an anti-CD20 antibody was thus effective in retarding tumor growth in multiple solid tumor models and augmenting immunotherapy in a tumor vaccine model. These studies raise the possibility that B-cell depletion may be a useful adjunct in human immunotherapy trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 2×
“We further characterized the CD8 T cells by measuring their expression of the T-cell activation marker, CD25.(30,31) In the control tumors, only 27.”
BackgroundSuzuki, E., Kapoor, V., Cheung, H.-K., Ling, L. E., DeLong, P. A., Kaiser, L. R., & Albelda, S. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0611 · Cited by 65
Cited by
B cells, plasma cells and antibody repertoires in the tumour microenvironment
Sharonov, G. V., Serebrovskaya, E. O., Yuzhakova, D. V., Britanova, O. V., & Chudakov, D. M. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0257-x · Cited by 627
Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer
Wang, S.-S., Liu, W., Ly, D., Xu, H., Qu, L., & Zhang, L. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-018-0027-x · Cited by 524
B lymphocytes and cancer: a love-hate relationship
Yuen, G. J., Demissie, E., & Pillai, S. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.10.010 · Cited by 433
“In addition, the success of B cell depletion in impeding tumor growth in mouse models has been mixed: in one study, B cell depletion using an anti-CD20 antibody was able to impede tumor growth in several solid tumor models, as well as bolster the response to a tumor vaccine [77] in mice.”
CD20+ B Cells: The Other Tumor-Infiltrating Lymphocytes
Nelson, B. H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001323 · Cited by 416
Immunosuppressive Mechanisms of Regulatory B Cells
Catalán, D., Mansilla, M. A., Ferrier, A., Soto, L., Oleinika, K., Aguillón, J. C., & Aravena, O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.611795 · Cited by 399
Metadata
- Authors
- Kim, S., Fridlender, Z. G., Dunn, R., Kehry, M. R., Kapoor, V., Blouin, A., Kaiser, L. R., & Albelda, S. M.
- Venue
- Journal of Immunotherapy
- Published
- 2008-06
- Volume
- 31
- Issue
- 5
- Pages
- 446-457
- ISSN
- 1524-9557 (ISSN-L)
- OpenAlex
- W2048862678
- Cited by
- 75
- References
- 2
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: B-cell Depletion Using an Anti-CD20 Antibody Augments Antitumor Immune Responses and Immunotherapy in Nonhematopoetic Murine Tumor Models. https://app.cochat.ai/papers/10.1097/cji.0b013e31816d1d6a
- The paper
- Kim, S., Fridlender, Z. G., Dunn, R., Kehry, M. R., Kapoor, V., Blouin, A., Kaiser, L. R., & Albelda, S. M. (2008). B-cell Depletion Using an Anti-CD20 Antibody Augments Antitumor Immune Responses and Immunotherapy in Nonhematopoetic Murine Tumor Models. Journal of Immunotherapy. https://doi.org/10.1097/cji.0b013e31816d1d6a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.